Results 71 to 80 of about 5,946,067 (288)

Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.

open access: yesJAMA Oncology, 2020
Importance Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown.
C. V. Van Poznak   +14 more
semanticscholar   +1 more source

Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay

open access: yesBMC Cancer, 2009
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effects in vitro and in patients.
Dexel Susanne   +7 more
doaj   +1 more source

Zoledronic acid in breast cancer: latest findings and interpretations

open access: yesTherapeutic Advances in Medical Oncology, 2011
The intravenous nitrogen-containing bisphosphonate zoledronic acid has been shown to block multiple steps in tumor metastasis (e.g. angiogenesis, invasion, adhesion, proliferation) in preclinical and translational studies.
Michael Gnant
doaj   +1 more source

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu   +2 more
wiley   +1 more source

Zoledronic acid and teriparatide have a complementary therapeutic effect on aseptic loosening in a rabbit model

open access: yesBMC Musculoskeletal Disorders, 2021
Background Revisions are mainly caused by wear debris-induced aseptic loosening. How to effectively suppress debris-induced periprosthetic osteolysis has become an urgent problem.
Peng Wang   +5 more
doaj   +1 more source

Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements [PDF]

open access: yes, 2015
INTRODUCTION: Our objective was to determine effects of zoledronic acid (ZA) on atrial electrophysiological parameters and electrocardiographic measurements.
Allen, Matthew R.   +4 more
core   +1 more source

Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment

open access: yesScientific Reports, 2020
Zoledronic acid (ZOL) is a third generation bisphosphonate which can be used as a drug for the treatment of osteoporosis and metastasis. In this study, graphene oxide (GO) is conjugated with ZOL, and the nanostructured material is evaluated in terms ...
Gökçen Boran   +4 more
semanticscholar   +1 more source

Dimethyl‐, Diethyl‐, and Propylene Carbonates: An Emerging Class of Green Solvents for Organic Synthesis

open access: yesThe Chemical Record, EarlyView.
This review highlights recent advances in the use of organic carbonates, dimethyl carbonate (DMC), diethyl carbonate (DEC), and propylene carbonate (PC), as solvents in organic synthesis. Based on over seventy studies from the past 6 years, it shows their application in different organic reaction types, emphasizing their role in safer and more ...
Gabriela T. Quadros   +5 more
wiley   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott   +8 more
wiley   +1 more source

Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells [PDF]

open access: yes, 2017
Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice.
Abdullah, MI, Abed, MN, Richardson, A
core   +1 more source

Home - About - Disclaimer - Privacy